Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4497-4513

  Micci, Luca ^a   Ryan, Emily S ^b   Fromentin, Rémi ^c   Bosinger, Steven E ^a,c   Harper, Justin L ^a   He, Tianyu ^d   Paganini, Sara ^a   Easley, Kirk A ^e   Chahroudi, Ann ^a   Benne, Clarisse ^f   Gumber, Sanjeev ^a,c   McGary, Colleen S ^a   Rogers, Kenneth A ^a   Deleage, Claire ^g   Lucero, Carissa ^g   Byrareddy, Siddappa N ^a   Apetrei, Cristian ^d   Estes, Jacob D ^g   Lifson, Jeffrey D ^g   Piatak, Michael ^g   Chomont, Nicolas ^b   Villinger, Francois ^a   Silvestri, Guido ^a   Brenchley, Jason M ^h   Paiardini, Mirko ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e EMORY UNIVERSITY   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; EMCITRABINE; RALTEGRAVIR; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 21 IMMUNOGLOBULIN FC FRAGMENT; RITONAVIR; TENOFOVIR; UNCLASSIFIED DRUG; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE; VIRUS DNA; VIRUS RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MORBIDITY; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TH22 CELL; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; IMMUNOLOGY; INFLAMMATION; INTESTINE; METABOLISM; PATHOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; TH17 CELL; TIME FACTOR; VIROLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; DNA, VIRAL; INFLAMMATION; INTERLEUKINS; INTESTINES; MACACA MULATTA; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TH17 CELLS; TIME FACTORS;

EID: 84948807352     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81400     Document Type: Article

References (71)

1. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633-645.
2. Siliciano JD, Siliciano RF. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol. 2014;134(1):12-19.
3. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533.
4. Katlama C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109-2117.
5. Yang L, et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature. 2008;454(7202):350-352.
6. Nurieva R, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480-483.
7. Korn T, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484-487.
8. Brenchley JM, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lenti-viral infections. Blood. 2008;112(7):2826-2835.
9. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371.
10. Estes JD, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6(8):e1001052.
11. + lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 2012;5(6):646-657.
12. Paiardini M. Th17 cells in natural SIV hosts. Curr Opin HIV AIDS. 2010;5(2):166-172.
13. Cecchinato V, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 2008;1(4):279-288.
14. Raffatellu M, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008;14(4):421-428.
15. Micci L, et al. Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood. 2012;120(19):3925-3935.
16. Pallikkuth S, et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with inter-leukin (IL)-21. PLoS Pathog. 2013;9(7):e1003471.
17. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther. 2010;10(5):807-817.
18. + T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. J Immunol. 2010;185(3):1650-1659.
19. Picker LJ, et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest. 2006;116(6):1514-1524.
20. Villinger F, et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine. 2004;22(25-26):3510-3521.
21. White L, et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranu-lation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood. 2007;109(9):3873-3880.
22. Neumann B, Klippert A, Raue K, Sopper S, Stahl-Hennig C. Characterization of B and plasma cells in blood, bone marrow, and secondary lymphoid organs of rhesus macaques by multicolor flow cytometry. J Leukoc Biol. 2015;97(1):19-30.
23. Favre D, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5(2):e1000295.
24. + T cell activation in HIV-infected individuals. J Immunol. 2010;185(9):5169-5179.
25. Wakabayashi H, Oda H, Yamauchi K, Abe F. Lactoferrin for prevention of common viral infections. J Infect Chemother. 2014;20(11):666-671.
26. Merenstein D, et al. Colonization by Candida species of the oral and vaginal mucosa in HIV-infected and noninfected women. AIDS Res Hum Retroviruses. 2013;29(1):30-34.
27. Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425-435.
28. Landrø L, et al. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retro-viral therapy. Clin Exp Immunol. 2008;152(1):57-63.
29. Corfield AP. Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta. 2015;1850(1):236-252.
30. Yeaman MR, et al. Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochim Biophys Acta. 2007;1768(3):609-619.
31. Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol. 2004;172(8):4956-4963.
32. + T cells is characteristic of pathogenic simian immunodeficiency virus infection. J Virol. 2004;78(3):1464-1472.
33. + T cells. J Infect Dis. 2013;208(1):50-56.
34. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254(1):326-342.
35. Chomont N, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893-900.
36. + T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemest-rina model of human immunodeficiency virus type 1-infected patients on highly active antiretro-viral therapy. J Virol. 2003;77(8):4938-4949.
37. Shen A, et al. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol. 2007;81(4):1660-1670.
38. Micci L, et al. Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaque. Presented at: 8th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2015; Vancouver, British Columbia, Canada. Abstract MOAA0102.
39. + T-cell responses. Eur J Immunol. 2010;40(11):3085-3096.
40. Novy P, Huang X, Leonard WJ, Yang Y. Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection. J Immunol. 2011;186(5):2729-2738.
41. Yi JS, Ingram JT, Zajac AJ. IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J Immunol. 2010;185(8):4835-4845.
42. + T cell function. J Virol. 2011;85(2):733-741.
43. Ozaki K, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002;298(5598):1630-1634.
44. Ozaki K, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173(9):5361-5371.
45. Zotos D, et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med. 2010;207(2):365-378.
46. Ettinger R, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol. 2005;175(12):7867-7879.
47. Davis ID, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13(12):3630-3636.
48. Frederiksen KS, et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immuno-ther. 2008;57(10):1439-1449.
49. Schmidt H, et al. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res. 2010;16(21):5312-5319.
50. Shytaj IL, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog. 2012;8(6):e1002774.
51. Del Prete GQ, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58(11):6790-6806.
52. Whitney JB, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74-77.
53. Hansen SG, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013;502(7469):100-104.
54. Chahroudi A, Bosinger SE, Vanderford TH, Paiar-dini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science. 2012;335(6073):1188-1193.
55. Onlamoon N, et al. Soluble PD-1 rescues the pro-liferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology. 2008;124(2):277-293.
56. + T cells are associated with limited CCR5 expression. Nat Med. 2011;17(7):830-836.
57. Micci L, et al. CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLoS Pathog. 2014;10(10):e1004467.
58. Amara RR, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292(5514):69-74.
59. Vandergeeten C, et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014;88(21):12385-12396.
60. + T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci USA. 2009;106(19):8015-8020.
61. Fukazawa Y, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med. 2015;21(2):132-139.
62. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol. 1994;32(3):732-739.
63. Zimin AV, et al. A new rhesus macaque assembly and annotation for next-generation sequencing analyses. Biol Direct. 2014;9(1):20.
64. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
65. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2013;31(1):46-53.
66. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
67. Rotger M, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest. 2011;121(6):2391-2400.
68. Sereti I, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10(1):e1003890.
69. Somsouk M, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015;29(1):43-51.
70. Diggle PJ, Liang KY, Zeger SL. Analysis Of Longitudinal Data. 1st ed. Oxford, United Kingdom: Clarendon; 1994.
71. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121-130.